原発性免疫性血小板減少症の成人患者におけるエフガルティギモド PH20 皮下投与の安全性と有効性を評価する第 3 相試験 (ADVANCE SC+)
原発性免疫性血小板減少症の成人患者における Efgartigimod (ARGX-113) PH20 皮下投与の安全性と有効性を評価する第 3 相、多施設、非盲検、長期試験
The main aim of the study is to evaluate the safety and efficacy of efgartigimod PH20 SC (subcutaneous) in adult patients with primary immune thrombocytopenia (ITP). Participants who completed the 24-week trial period of the ARGX- 113-2004 trial are given the opportunity to enter into this open-label extension trial and receive efgartigimod PH20 SC.
Participants will be offered the opportunity to continue in this trial if they have completed the first 52-week treatment period unless efgartigimod becomes commercially available for patients with primary ITP or becomes available through another program for patients with primary ITP, whichever comes first. A maximum of three additional 52-week treatment periods will be offered to the participant to continue this trial.
The total trial duration per participant is up to 4 years (52-week treatment period, extendable with three additional 52-week treatment periods) + 8 weeks follow-up period.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Dublin、アイルランド
- Investigator site 3530003
-
-
-
-
Arkansas
-
Bentonville、Arkansas、アメリカ、72758
- Investigator Site 0010116
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20007
- Investigator site 0010045
-
-
Indiana
-
Fort Wayne、Indiana、アメリカ、46804
- Investigator Site 0010062
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- Investigator site US0010042
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73142
- Investigator Site 0010095
-
-
-
-
-
Buenos Aires、アルゼンチン
- Investigator Site 0540001
-
Buenos Aires、アルゼンチン
- Investigator site 540004
-
-
-
-
-
Coventry、イギリス
- Investigator site 440005
-
London、イギリス
- Investigator site UK044041
-
Penzance、イギリス、TR18 2PF
- Investigator site UK0440014
-
-
-
-
-
Ferrara、イタリア
- Investigator site 390043
-
Milan、イタリア
- Investigator Site 0390032
-
Naples、イタリア
- Investigator Site 0390044
-
Naples、イタリア
- Investigator site 390041
-
-
-
-
-
Garran、オーストラリア
- Investigator Site 0610012
-
West Perth、オーストラリア
- Investigator Site 0610003
-
Westmead、オーストラリア
- Investigator site 610005
-
-
-
-
-
Athens、ギリシャ
- Investigator site 300008
-
Thessaloniki、ギリシャ
- Investigator Site 0300009
-
-
-
-
-
Tbilisi、グルジア
- Investigator site 9950009
-
Tbilisi、グルジア
- Investigator site 9950011
-
Tbilisi、グルジア
- Investigator Site 9950007
-
-
-
-
-
Bangkok、タイ
- Investigator Site 0660002
-
Bangkok、タイ
- Investigator Site 0660003
-
Bangkok、タイ
- Investigator site 660005
-
Bangkok Noi、タイ
- Investigator Site 0660001
-
Chiang Mai、タイ、50200
- Investigator site 0660004
-
Khon Kaen、タイ
- Investigator site TH0660009
-
-
-
-
-
Sousse、チュニジア
- Investigator site 2610001
-
Tunis、チュニジア
- Investigator site 2160002
-
-
-
-
-
Reñaca、チリ
- Investigator site 0560003
-
Santiago、チリ
- Investigator site 560002
-
Temuco、チリ
- Investigator site 0560004
-
-
-
-
-
Adapazarı、トルコ(Türkiye)
- Investigator Site 0900007
-
Ankara、トルコ(Türkiye)
- Investigator Site 0900003
-
Ankara、トルコ(Türkiye)
- Investigator Site 0900015
-
Ankara、トルコ(Türkiye)
- Investigator Site 0900008
-
Izmir、トルコ(Türkiye)
- Investigator site 900004
-
Kocaeli、トルコ(Türkiye)
- Investigator Site 0900014
-
Mersin、トルコ(Türkiye)
- Investigator site 900010
-
Tekirdağ、トルコ(Türkiye)、59100
- Investigator site 0900017
-
Trabzon、トルコ(Türkiye)
- Investigator site 900019
-
-
-
-
-
Christchurch、ニュージーランド
- Investigator site 640005
-
-
-
-
-
Sarpsborg、ノルウェー、1714
- Investigator site 0470003
-
-
-
-
-
Plovdiv、ブルガリア
- Investigator Site 3590017
-
-
-
-
-
Lisbon、ポルトガル
- Investigator Site 3510007
-
Porto、ポルトガル
- Investigator site 3510004
-
Vila Nova de Gaia、ポルトガル
- Investigator site 3510001
-
-
-
-
-
Katowice、ポーランド、40-519
- Investigator site PL0480013
-
Nowy Sącz、ポーランド
- Investigator Site 0480026
-
Skorzewo、ポーランド
- Investigator Site 0480037
-
-
-
-
-
Aguascalientes、メキシコ
- Investigator site 520002
-
-
-
-
-
Irbid、ヨルダン
- Investigator site 9620001
-
-
-
-
-
Bucharest、ルーマニア
- Investigator Site 0400005
-
Bucharest、ルーマニア
- Investigator site 400012
-
Craiova、ルーマニア
- Investigator Site 0400007
-
-
-
-
-
Kirov、ロシア
- Investigator site 0070040
-
Moscow、ロシア
- Investigator Site 0070026
-
Nizhny Novgorod、ロシア
- Investigator Site 0070038
-
Novosibirsk、ロシア
- Investigator Site 0070037
-
-
-
-
-
Beijing、中国
- Investigator site 860013
-
Bengbu、中国
- Investigator Site 0860008
-
Huizhou、中国
- Investigator site 860055
-
Shenzhen、中国
- Investigator Site 0860015
-
Tianjin、中国
- Investigator Site 0860001
-
Wuhan、中国
- Investigator Site 0860010
-
Wuxi、中国
- Investigator Site 0860002
-
Zhengzhou、中国
- Investigator Site 0860011
-
Zhenjiang、中国
- Investigator site 860058
-
-
-
-
-
Johannesburg、南アフリカ
- Investigator site 270003
-
Observatory、南アフリカ
- Investigator site 270004
-
Pretoria、南アフリカ
- Investigator site 270001
-
Randburg、南アフリカ
- Investigator site 270002
-
-
-
-
-
Hirakata、日本、5731191
- Investigator site JP0810015
-
Iruma、日本
- Investigator Site 0810017
-
Kanagawa、日本
- Investigator Site 0810053
-
Kitakyushu、日本
- Investigator Site 0810051
-
Shibukawa、日本、377-0280
- Investigator site 0810016
-
Shimotsuke、日本
- Investigator site 810023
-
Tama、日本
- Investigator Site 0810038
-
-
-
-
-
Seoul、韓国
- Investigator site 820004
-
Seoul、韓国
- Investigator site KO0820007
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Ability to understand the requirements of the trial and provide written informed consent (including consent for the use and disclosure of research-related health information), willing and able to comply with the trial protocol procedures (including attending the required trial visits).
- Participants enrolled in the ARGX-113-2004 trial who completed the 24-week trial period.
- Agree to use contraceptives consistent with local regulations.
- In addition to the above criteria, for participants who want to continue receiving efgartigimod during an additional 52-week treatment period, the participant has completed a 52-week treatment period.
Exclusion criteria:
- Introduction or continuation of nonpermitted medications during the ARGX-113-2004 trial (such as anti-CD20 therapy, romiplostim, monoclonal antibodies, Fc fusion proteins, or live/live-attenuated vaccines).
- Use of any other investigational drug or participation in any other investigational trial.
- Known hypersensitivity reaction to efgartigimod PH20 SC or any of its excipients.
- Pregnant or lactating females and those who intend to become pregnant during the trial or within 90 days after last dose of efgartigimod PH20 SC.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:efgartigimod PH20 SC
Patients receiving efgartigimod PH20 SC treatment |
Subcutaneous injection with efgartigimod PH20 SC
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of AEs, AESIs, SAEs
時間枠:Up to 216 weeks
|
AE : adverse event ; SAE : Serious adverse event ; AESI : adverse event of special interest. |
Up to 216 weeks
|
|
Vital sign measurement: blood pressure in the overall population
時間枠:Up to 216 weeks
|
Up to 216 weeks
|
|
|
ECG: PR, QT and QRS interval in the overall population
時間枠:Up to 216 weeks
|
Up to 216 weeks
|
|
|
Laboratory safety evaluations: CRP analysis in the overall population
時間枠:Up to 216 weeks
|
Up to 216 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Extent of disease control defined as the percentage of weeks in the trial with platelet counts of ≥50×10E9/L
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Proportion of participants with overall platelet count response defined as achieving a platelet count of ≥50×10E9/L on at least 4 occasions at any time during the 52-week treatment period
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Mean change from baseline in platelet count at each visit
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
For participants rolling over from the ARGX-113-2004 trial with a platelet count of <30×10E9/L: time to response defined as the time to achieve 2 consecutive platelet counts of ≥50×10E9/L
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
The percentage of weeks in the trial with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
In patients with a baseline platelet count of <15×10E9/L in the current trial (ARGX-113-2005), the percentage of weeks in the trial with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
In participants with the first exposure to efgartigimod PH20 SC, the proportion of patients who achieve a sustained platelet response defined as achieving platelet counts of ≥50×10E9/L for at least 4 of the 6 visits between week 19 and week 24
時間枠:5 weeks (from week 19 to week 24)
|
5 weeks (from week 19 to week 24)
|
|
|
In participants with the first exposure to efgartigimod PH20 SC, the proportion of patients achieving platelet counts of ≥50×10E9/L for at least 6 of the 8 visits between week 17 and week 24
時間枠:7 weeks (from week 17 to week 24)
|
7 weeks (from week 17 to week 24)
|
|
|
Proportion of participants for whom dose and/or frequency of concurrent ITP therapies have been reduced compared to baseline
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Rate of receipt of rescue therapy (rescue per participant per month)
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Incidence of the WHO-classified bleeding events
時間枠:Up to 52 weeks
|
WHO : World Health Organization |
Up to 52 weeks
|
|
Serum efgartigimod concentration observed predose (Ctrough)
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Change from baseline in FACIT-fatigue at planned visits
時間枠:Up to 52 weeks
|
The Functional Assessment of Chronic Illness Therapy Fatigue (FACIT- fatigue) scale is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured by recording item responses on a 4-point Likert scale ranging from 0 "not at all" to 4 "very much." |
Up to 52 weeks
|
|
Change from baseline in FACT-Th6 at planned visits
時間枠:Up to 52 weeks
|
The Functional Assessment of Cancer Therapy questionnaire-Th6 (FACT-Th6) uses the Likert scale, with participants rating their degree of concern in the past 7 days. The 6 selected items pertain to ability to do usual activities, worry about problems with bleeding or bruising, worry about the possibility of serious bleeding, avoidance of physical or social activity because of concern with bleeding or bruising and frustration due to the inability to carry out usual activities. |
Up to 52 weeks
|
|
Change from baseline in SF-36 at planned visits
時間枠:Up to 52 weeks
|
The SF-36 is a 36-item scale constructed to survey health-related QoL on 8 domains: limitations in physical activities due to health problems; limitations in social activities due to physical or emotional problems; limitations in usual role activities due to physical health problems; bodily pain; general mental health (psychological distress and well being); limitations in usual role activities due to emotional problems; vitality (energy and fatigue); and general health perceptions. |
Up to 52 weeks
|
|
Change from baseline in ITP-PAQ at planned visits
時間枠:Up to 52 weeks
|
The ITP-Patient Assessment Questionnaire (ITP-PAQ) is a 44-item questionnaire to assess the health-related QoL in adults with ITP. It includes scales for physical health (symptoms, fatigue/sleep, bother, and activity), emotional health (psychological and fear), overall QoL, social activity, women's reproductive health, and work. |
Up to 52 weeks
|
|
Pharmacodynamics markers: total IgG
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Percentage of participants who performed self-administration at home over time
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Percentage of caregivers who administered the injection to the patient at home over time
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Number of training visits needed for the participant or caregiver to be competent to start administering efgartigimod PH20 SC
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Percentage of self- or caregiver-supported administrations at home
時間枠:Up to 52 weeks
|
Up to 52 weeks
|
|
|
Incidence of antibodies to efgartigimod
時間枠:Up to 216 weeks
|
Up to 216 weeks
|
|
|
Titers of antibodies to efgartigimod
時間枠:Up to 216 weeks
|
Up to 216 weeks
|
|
|
Presence of NAb against efgartigimod
時間枠:Up to 216 weeks
|
NAb : Neutralizing antibodies |
Up to 216 weeks
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- ARGX-113-2005
- 2024-513147-90-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。